Latest Ratios: P/E Ratio -0.8x · EV/EBITDA N/A · ROE -950.1%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $8M | $6M | $14M | $111M | $98M | $105M | $62M | $138M | $269M | $325M |
| Enterprise Value | $4M | $6M | $5M | $14M | $105M | $87M | $84M | $58M | $133M | $256M | $304M |
| P/E Ratio → | -0.83 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 103.14 | 29.48 | 82.15 | 97.02 | 724.36 | 87.77 | 221.06 | 561.65 | 565.08 |
| P/B Ratio | 7.56 | 9.31 | 7.15 | — | 22.71 | 9.49 | 5.48 | 26.29 | 36.43 | 24.18 | 15.81 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 78.65 | 29.93 | 77.91 | 86.18 | 580.96 | 81.51 | 212.48 | 535.16 | 528.01 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -7463.8% | -1519.7% | -553.4% | 36.9% | 97.2% | 49.6% | 17.3% | -44.1% | -29.5% |
| Operating Margin | — | — | -13794.8% | -2441.1% | -880.3% | -1244.3% | -10709.7% | -2001.8% | -2256.3% | -2589.8% | -1320.8% |
| Net Profit Margin | — | — | -13700.0% | -2425.8% | -880.7% | -1243.4% | -10347.6% | -2071.7% | -2237.9% | -2569.5% | -1789.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -950.1% | -950.1% | -949.3% | -703.6% | -156.0% | -85.4% | -139.3% | -477.4% | -187.5% | -77.6% | -59.9% |
| ROA | -230.6% | -230.6% | -236.8% | -181.1% | -93.3% | -64.5% | -96.5% | -208.7% | -140.2% | -69.1% | -57.3% |
| ROIC | — | — | — | — | — | — | — | — | — | — | -231.6% |
| ROCE | -694.5% | -694.5% | -2046.3% | -416.8% | -130.7% | -81.0% | -135.9% | -376.8% | -187.1% | -77.9% | -44.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.59 | 0.59 | 1.14 | — | 0.33 | 0.18 | 0.03 | 0.48 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.20 | -1.70 | — | -1.17 | -1.06 | -1.08 | -1.87 | -1.41 | -1.14 | -1.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -1983.50 | — | -5000.33 | -130.33 | — | — | -4.94 |
Net cash position: cash ($2M) exceeds total debt ($528000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | 1.12 | 1.13 | 0.40 | 2.19 | 3.63 | 5.33 | 1.59 | 2.44 | 5.71 | 15.18 |
| Quick Ratio | 1.12 | 1.12 | 1.13 | 0.40 | 2.19 | 3.63 | 5.33 | 1.59 | 2.39 | 5.63 | 15.08 |
| Cash Ratio | 1.03 | 1.03 | 1.02 | 0.31 | 2.05 | 3.47 | 5.04 | 1.40 | 2.10 | 5.44 | 14.79 |
| Asset Turnover | — | — | 0.02 | 0.16 | 0.14 | 0.06 | 0.01 | 0.09 | 0.10 | 0.04 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | 89.50 | 3.67 | 3.61 | 5.53 |
| Days Sales Outstanding | — | — | — | 48.21 | 54.26 | 52.86 | 584.00 | 75.57 | 160.02 | 72.39 | 46.89 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $7M | $3M | $1M | $1M | $1M | $674579 | $376289 | $284279 | $282671 | $61987 |
Imminent liquidity and insolvency
According to recent financial data, BioCardia's price-to-book ratio of 8.94 suggests that the market is pricing the firm as a speculative call option on clinical trial outcomes rather than a traditional operating business, given the absence of meaningful revenue or earnings to support standard valuation multiples.
The lack of P/E and EV/EBITDA multiples underscores the company's pre-revenue status, where traditional valuation metrics fail to capture the underlying risk profile. Investors should monitor whether the current premium to book value is supported by the intellectual property of the Helix delivery system or if it represents an overvaluation in the face of severe capital constraints.
Based on the most recent quarterly filings, the company's current ratio has deteriorated to 0.41, indicating that current liabilities significantly outweigh available liquid assets, which leaves the firm in a precarious position to meet its near-term operational obligations without immediate external financing or strategic intervention.
The rapid decline in the quick ratio to 0.41 highlights a severe liquidity crunch that limits the company's ability to sustain its current R&D burn rate. This level of liquidity suggests that the firm is highly vulnerable to even minor delays in clinical trial milestones or unexpected increases in regulatory compliance costs.
As reported in financial statements, the company's days payable outstanding has fluctuated wildly, reaching as high as 994 days in 2025Q3, which suggests that BioCardia is relying heavily on extended supplier credit to manage its cash position rather than generating internal efficiencies through its core business activities.
The extreme volatility in DPO metrics indicates a lack of operational control over working capital, likely driven by the need to preserve cash for critical clinical trial expenditures. This reliance on vendor financing is unsustainable and warrants further investigation into the company's ability to maintain its supply chain relationships under continued financial pressure.
The most commonly misapplied metric for BioCardia is the price-to-book ratio, which obscures the reality that the company's assets are primarily intangible and rapidly depreciating in value due to the ongoing cash burn required to sustain clinical development programs without any offsetting commercial revenue streams.
Analysts should instead focus on the cash runway and the burn rate relative to the remaining liquidity, as book value provides a false sense of security in a firm that is effectively consuming its own equity. Relying on P/B ignores the structural reality that the company's primary assets are clinical trials that may never reach commercialization.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCDA stock.
BioCardia, Inc.'s current P/E ratio is -0.8x. The historical average is 13.8x.
BioCardia, Inc.'s return on equity (ROE) is -950.1%. The historical average is -88.0%.
Based on historical data, BioCardia, Inc. is trading at a P/E of -0.8x. Compare with industry peers and growth rates for a complete picture.